Colitis Clinical Trial
Official title:
An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis
Verified date | March 8, 2011 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will determine if medical treatment of colitis (inflammation of the colon
resulting in loose bowel movements, rectal bleeding, and belly pain) that is used for other
colitis conditions, such as Crohn's disease and ulcerative colitis, is safe and effective for
treating colitis in patients with Hermansky-Pudlak syndrome (HPS). HPS is a hereditary
disorder that causes albinism, visual impairment, and abnormal bleeding. Some patients also
develop colitis, pulmonary fibrosis, and kidney disease.
Patients with HPS and colitis who are 18 years of age or older may be eligible for this
study. Participants receive treatment for their colitis symptoms with one or more of several
study drugs, which include mesalamine (5-ASA), corticosteroids, infliximab and
6-mercaptopurine, adalimumab and tacrolimus. The drugs are added to the treatment plan one at
a time to find the combination that works best for the individual patient. Patients who
respond to one or more of the medications may continue treatment with that same combination
for up to 6 months.
Regular clinic visits are scheduled for blood tests, symptoms ratings questionnaires and
periodic physical examinations and colonoscopies to measure the response to treatment and
evaluate any side effects.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 8, 2011 |
Est. primary completion date | March 8, 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: A subject is eligible for the study if all of the following criteria are met: - Has given written informed consent prior to screening. - Age 18 years old or greater. - Has confirmed diagnosis of HPS prior to screening. - Has confirmed diagnosis of IBD prior to screening. - The presence of active disease as defined by a SCCAI score greater than or equal to 5. - Negative results on stool examination for culture of enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, Vibrio, E. coli O157/H7), Clostridium difficile toxin assay, enteric parasites and their ova (including Giardia and Cryptosporidia). - If currently receiving medication for their IBD, patients may be on a stable regimen of one or a combination of the following drug doses and durations: Corticosteroids (less than or equal to 25 milligrams Prednisone or Prednisone equivalent per day) - greater than or equal to 4 weeks. 5-ASA Sulfasalazine - greater than or equal to 4 weeks. Azathioprine/6-MP/thioguanine with stable dose for eight weeks - greater than or equal to 12 weeks. (NOTE: Patients receiving azathioprine/6-MP/thioguanine must have been on a stable dose of this medication for greater than or equal to 8 weeks) Probiotics (live bacterial dietary supplements) - greater than or equal to 4 weeks. Prebiotics (dietary supplements to produce biologically active substances) - greater than or equal to 4 weeks. Infliximab (5 to 10 mg/kg IV) - greater than 8 weeks or no response within 4 weeks of an induction dose of 3 infusions. Adalimumab (40 to 80 mg subq) - greater than or equal to 4 weeks or no response within 2 weeks after induction dose of 2 injections. EXCLUSION CRITERIA: A subject is excluded from the study if any of the following criteria are met: GENERAL CRITERIA: - Has any clinically significant disease (e.g., renal, hepatic, neurological, cardiovascular, pulmonary, endocrinology, psychiatric, hematological, urologic, or other acute or chronic illness) that in the opinion of the investigator would make the subject an unsuitable candidate for this trial. - Inability to meet any of the above inclusion criteria. - Is a woman who has a positive serum pregnancy test or who is breast-feeding. - Has any of the following clinical chemistry values: 1. AST greater than 2.5 times the upper limit of normal (ULN). 2. ALT greater than 2.5 times the ULN. 3. Serum bilirubin greater than 1.5 times the ULN. 4. Serum creatinine greater than 1.5 times the ULN. 5. Alkaline phosphatase greater than 2.5 times the ULN. - Has a hemoglobin level less than 8.0 g/dL or hematocrit less than 26 percent. - Has a PT INR greater than 1.3 or a PTT greater than 3 seconds compared to control value. - Has the following cell counts: 1. Platelet count less than 80,000 or greater than 950,000. 2. White blood cell count less than 1200. 3. Neutrophil count less than 700. - Has a current infection requiring intravenous antibiotics, a serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia). - Has a history of cancer within the past 5 years, with the exception of excised basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ. - Had a dependency for any illicit drug, chemical or alcohol within the past 5 years. - Has a history of active tuberculosis (TB) (or a positive PPD skin test or chest x-ray with findings suggestive of old TB infection including calcified nodular lesions, apical fibrosis, or pleural scarring), acute or chronic hepatitis B, hepatitis C, human immunodeficiency virus (HIV). - History of central nervous system demyelinating disease, or systemic lupus erythematosus. - Unable to keep to the scheduled appointments and other test to watch for changes in symptoms and side effects of treatment. GASTROINTESTINAL CRITERIA: - History of colectomy, partial colectomy, current ostomy, pouchitis, or small bowel resection within the past 6 months, or short gut syndrome. - Presence of current active bowel obstruction, intestinal perforation, known presence of high grade stricture, history of toxic megacolon, history of colonic epithelium high-grade dysplasia or a dysplasia-associated lesion or mass that does not resemble an adenoma (that is a mass lesion, stricture, or broad-based tumor with dysplasia). |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006 Apr 1;23(7):841-55. Review. — View Citation
Cappell MS. Gastrointestinal endoscopy in high-risk patients. Dig Dis. 1996 Jul-Aug;14(4):228-44. Review. — View Citation
D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006 Dec;8(6):506-12. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To detect patterns of immune abnormalities in the colitis associated with Hermansky-Pudlak Syndrome (HPS). | 60 weeks | ||
Secondary | Document the clinical response to and tolerance of conventional inflammatory bowel disease (IBD) therapy for HPS patients with active colitis associated with Hermansky-Pudlak Syndrome (HPS). | 60 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00272818 -
Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
|
||
Completed |
NCT01369355 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
|
Phase 3 | |
Completed |
NCT02709213 -
Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
|
||
Completed |
NCT00533078 -
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
|
Phase 2 | |
Terminated |
NCT00184171 -
Treatment of Microscopic Colitis
|
N/A | |
Recruiting |
NCT05333978 -
Optoacoustic Detection of Inflammation Using MSOT Device
|
N/A | |
Not yet recruiting |
NCT06424769 -
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
|
N/A | |
Recruiting |
NCT02768038 -
Intestinal Microbiome and Chronic Inflammatory Bowel Disease
|
||
Recruiting |
NCT04272307 -
MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
|
||
Completed |
NCT05514561 -
FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
|
||
Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
Recruiting |
NCT02687724 -
Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis
|
Phase 4 | |
Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01326013 -
A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel
|
Phase 2 | |
Not yet recruiting |
NCT05726396 -
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
|
Phase 2 | |
Completed |
NCT05414552 -
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
|
||
Recruiting |
NCT04407247 -
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT01369329 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
|
Phase 3 | |
Completed |
NCT01369342 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
|
Phase 3 | |
Terminated |
NCT00936585 -
NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease
|
N/A |